66th ASH Annual Meeting: 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster II

Symposia: Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products Oral and Poster Abstracts
Poster

Research, Antibody Therapy, Lymphoid Leukemias, Acute Myeloid Malignancies, ALL, AML, Fundamental Science, Clinical trials, Adult, Clinical Practice (Health Services and Quality), Lymphomas, Translational Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, B Cell lymphoma, Clinical Research, Pediatric, Diseases, Immune mechanism, Cell expansion, Treatment Considerations, Biological therapies, Immunology, Immunotherapy, Lymphoid Malignancies, Metabolism, Young adult , Biological Processes, Myeloid Malignancies, Emerging technologies, Technology and Procedures, Gene editing, Study Population, Human, Transplantation (Allogeneic and Autologous)

Halls G-H (San Diego Convention Center)

3470

Cost-Effective Manufacture and Promising Initial Efficacy of huCART19 Cells Manufactured Using the Clinimacs Prodigy Platform

Allison Barz Leahy, MD, MSc¹, Jennifer Brogdon, PhD², Lucy Cain, MBBS, FRACP³, Amanda M. Dinofia, MD, MSCE¹^*, Joseph A. Fraietta, PhD⁴^*, Richard Hanna, MS³^*, Stephan Kadauke, MD, PhD³, Raabia Khan³^*, Yimei Li, PhD¹^*, Shannon L. Maude, MD⁵, Regina M. Myers, MD¹, Laura Shinehouse³^*, Anna Sparrow, MSN, MPH, RN³^*, Melissa Varghese³^*, Lei Wang, PhD³^*, Yongping Wang, MD, PhD⁶^* and Stephan A. Grupp, MD, PhD⁷

¹Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA
²Novartis Institutes For Biomedical Research, Cambridge, MA
³Children's Hospital of Philadelphia, Philadelphia, PA
⁴Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
⁵The Children's Hospital of Philadelphia, Philadelphia, PA
⁶Children’s Hospital of Philadelphia, Philadelphia, PA
⁷Children’s Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

3471

Development of a UM171-Supported, CD33 Epitope-Engineered Blood Stem Cell Graft for Advanced AML Therapies

Bernhard Lehnertz, PhD¹^*, Maéva Langouët, PhD¹^*, Susan Moore, PhD²^*, Nadine Mayotte, MS³^*, Tara Macrae⁴^*, Etienne Gagnon, PhD⁵^* and Guy Sauvageau, MD/PhD^1,3

¹ExCellThera, Montreal, QC, Canada
²Université de Montréal, Montreal, QC, Canada
³Institut de recherche en Immunologie et Cancer, Université de Montréal, Montreal, QC, Canada
⁴IRIC, Université de Montréal, Montreal, QC, CAN
⁵IRIC, Université de Montréal, Montreal, QC, Canada

3472

Deciphering Minor Histocompatibility Antigen Immunoreactivity through Optimized T Cell Expansion Strategies

Annabelle Minguy¹^*, Jessica Trottier, MSc¹^*, Jaime Leonel Sanchez-Dardon, MSc¹^*, Cédric Mathieu, PhD¹^*, Jean-Philippe Bastien, PhD¹^*, Cédric Carli, PhD¹^*, Claude Perreault, MD^2,3, Jean-Sebastien Delisle, MD, PhD^1,3, Vibhuti Dave, PhD^1,4^* and Denis-Claude Roy, MD^1,3

¹Hematology-Oncology and Cell Therapy University Institute, Hôpital Maisonneuve-Rosemont Research Center, Montreal, QC, Canada
²Institut de recherche en immunologie et cancer (IRIC), Université de Montréal, Montréal, QC, Canada
³Department of Medicine, Université de Montréal, Montréal, QC, Canada
⁴Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montréal, QC, Canada

3473

In Vivo Persistence and Function of CAR19 T-Cell Products for Pediatric B-Cell Acute Lymphoblastic Leukemia Are Impacted By Media, Cytokine Supplementation and Metabolite Bioavailability during Ex Vivo Manufacturing

Caitlin R. Hopkins¹^*, Amanda M. DiNofia, MD, MSCE²^*, Shannon L. Maude, MD², Gregory M. Chen, MD, PhD¹^*, Kwame Attah M. Boateng-Antwi, PhD²^*, Jessica Perazzelli²^*, Andres F. Mendez Corea²^*, Alexander Shestov, PhD³^*, Mercy Gohil¹^*, Yimei Li, PhD⁴^*, Wei-Ting Hwang⁵^*, Bakir Valentić¹^*, Shannon Christensen, PhD⁶^*, Julie Jadlowsky, PhD¹^*, Regina M. Myers, MD, MSCE²^*, Caroline Diorio, MD², Megan M. Davis, PhD⁶^*, Theresa Colligon¹^*, Gabriela Plesa¹^*, Don L. Siegel, MD, PhD⁷, Bruce Levine, PhD^6,8, Carl H. June, MD^6,9, Roddy S. O'Connor, PhD¹⁰^*, Stephan A. Grupp, MD, PhD^2,11 and Joseph A. Fraietta, PhD^3,12^*

¹Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
²Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA
³Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
⁴Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
⁵Department of Biostatistics, Epidemiology, and Informatics, The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
⁶Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA
⁷University of Pennsylvania, Philadelphia, PA
⁸Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA
⁹Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
¹⁰Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
¹¹Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia
¹²Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

3474

Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells

Bryan Hancock, PhD¹^*, Jonatan Tuncel, PhD¹^*, Kyla Omilusik, PhD¹^*, Alison O'Connor, MS¹^*, Bi-Huei Yang, PhD¹^*, Matthew Haynes, MS¹^*, Amanda Yzaguirre, PhD¹^*, Karina Palomares¹^*, Sandeep Kothapally Hanok¹^*, Matthew Denholtz, PhD¹^*, Martin Hosking, PhD¹^*, Eigen Peralta, PhD¹^*, Tom Lee, PhD¹^*, Raedun Clarke, PhD¹^*, Sjoukje Van Der Stegen, PhD²^*, John Goulding¹^*, Jode Goodridge, PhD¹^*, Michel Sadelain, MD PhD² and Bahram Valamehr, PhD¹

¹Fate Therapeutics, San Diego, CA
²Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY

3475

Clinical Evaluation of Fast-in-Time (FIT) Anti-CD19 CAR T—a Non-Viral, 2-Day Rapid Manufacture CAR T-Cell Therapy for B-Cell Malignancies

Ping Li¹^*, Jian Ge, PhD², Shiguang Ye¹^*, Lili Zhou¹^*, Yiming Gong, MD³^*, Huaying Ruan, MN³^*, Hosein Kouros-Mehr³^* and Aibin Liang, MD¹^*

¹Department of Hematology, Tongji Hospital of Tongji University, Shanghai, China
²The First Affiliated Hospital, Hefei, China
³Shanghai First Song Therapeutics, Shanghai, China

3476

Global Manufacturing Experience with Idecabtagene Vicleucel in Patients with Relapsed and Refractory Multiple Myeloma

Surbhi Sidana, MD¹, Christof Scheid²^*, Peter J. Mueller³^*, Petra Schuberth³^*, Hardik Modi⁴^*, Peter Krengel⁴^*, Romain Piault³^*, Xiaobo Zhong⁴^* and Paula Rodríguez-Otero, MD, PhD⁵^*

¹Stanford University School of Medicine, Stanford, CA
²University of Cologne, Cologne, Germany
³Bristol Myers Squibb, Boudry, Switzerland
⁴Bristol Myers Squibb, Princeton, NJ
⁵Clínica Universidad de Navarra, Pamplona, Spain

3477

Improvements in Axicabtagene Ciloleucel Manufacturing Result in High Delivery Success and More Predictable Turnaround Time for Patients with Relapsed/Refractory Large B-Cell Lymphoma

David B. Miklos, MD, PhD¹, Wike Tong, MS²^*, Eric Kim, BS²^*, Brandon Kerr, BS, MA²^*, Morgan Neuwirth, BS²^*, Laura Alquist, BSBM²^* and Clare Spooner, MBBS, BSc²^*

¹Stanford University, Stanford, CA
²Kite, a Gilead Company, Santa Monica, CA

3478

Innovative Bone Marrow CAR-T Cell Manufacturing for AML: Enhancing Viability and Tumor Migration

Jose Antonio Bejarano Garcia¹^*, Daniel Primo, PhD²^*, Maria Jose Palacios Barea¹^*, Belén Sierro¹^*, Beatriz Guijarro-Albaladejo¹^*, Xian Weng, PhD²^*, Miranda Omenaca²^*, Estefania Garcia-Guerrero, PhD¹^*, Joan Ballesteros, PhD²^* and Jose Antonio Pérez-Simón, MD, PhD¹

¹Instituto de Biomedicina de Sevilla (Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Sevilla (US), Hospital Universitario Virgen del Rocío (HUVR))., Sevilla, Spain
²Vivia Biotech, Tres Cantos, Spain

3479

Automated Rapid CAR-T Cell Manufacturing Process, Starting from Whole Blood, on a Novel Closed Platform

Silin Sa, Ph.D.¹^* and Liping Yu, PhD²

¹Applied Cells, Santa Clara, CA
²Applied Cells, Inc., Santa Clara, CA

3480

FAS Ablation Confers Resistance to Allogeneic CAR-T Rejection By T Cells in Absence of NK Cell Sensitization

Silvia Menegatti, PhD¹^*, Sheila Lopez-Cobo, PhD¹^*, Aurelien Sutra Del Galy¹^*, Jaime Fuentealba, PhD¹^*, Lisseth Silva¹^*, Laeticia Perrin¹^*, Sandrine Heurtebise-Chrétien¹^*, Valentine Pottez-Jouatte, PhD^1,2^*, Aurélie Darbois¹^*, Nina Burgdorf¹^*, Albane Simon³^*, Marguerite Laprie-Santenac, PharmD³^*, Michael Saitakis, PhD⁴^*, Bruce Wick, PhD^5,6,7^*, Beau R Webber, PhD^5,6,7^*, Branden S Moriarity, PhD^5,6,7^*, Olivier Lantz, MD, PhD¹^*, Sebastian Amigorena, PhD¹^* and Laurie Menger, PhD³^*

¹Institut Curie, PSL University, INSERM U932, Immunity and Cancer, Paris, France
²CellAction (Cell therapy Acceleration and Innovation), Institut Curie, Suresnes, France
³Gustave Roussy, Paris-Saclay University, INSERM U1015, Villejuif, France
⁴Mnemo Therapeutics, Paris, France
⁵Department of Pediatrics, University of Minnesota, Minneapolis, MN
⁶Masonic Cancer Center, University of Minnesota, Minneapolis, MN
⁷Center for Genome Engineering, University of Minnesota, Minneapolis, MN

3481

KITE-753: An Autologous Rapid Manufactured Anti-CD19/CD20 CAR-T Product for the Treatment of B-Cell Malignancies

Jodi L Murakami^*, Claudia I Guevara^*, Qi Cai^*, Hsing-Chuan Tsai^*, Saikat Banerjee^*, Da Ming Ou^*, Sean C Yoder^*, Sophie Viaud^*, Quinn Walker^*, Sunanda Kumar^*, Beata Berent-Maoz^*, Gunce E Cinay^*, Emily Vincent^*, John L Langowski^* and David Barrett^*

Kite, a Gilead Company, Santa Monica, CA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH